Treatment Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on Feb 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of venetoclax (Venclexta) modification or early treatment ending on the outcomes of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).  This study concluded that venetoclax treatment modification did not impact outcomes but the early ending of...

Read More

Allogenic versus autologous hematopoietic stem cell transplant for patients with acute promyelocytic leukemia

Allogenic versus autologous hematopoietic stem cell transplant for patients with acute promyelocytic leukemia

Posted by on Feb 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of allogeneic (allo) and autologous (auto) hematopoietic stem cell transplant (HSCT) for patients with acute promyelocytic leukemia (APL) in second complete remission (CR2).  This study concluded that autoHSCT resulted in better outcomes for these patients.   Some background...

Read More

Nivolumab improves survival in patients with non-small cell lung cancer in the long-term.

Nivolumab improves survival in patients with non-small cell lung cancer in the long-term.

Posted by on Feb 28, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...

Read More

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Posted by on Feb 28, 2021 in Breast cancer | 0 comments

In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...

Read More

Comparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.

Comparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors compared a high-dose radiation (24 Gy) in 12 parts with a low-dose radiation (4 Gy) in 2 parts in patients with slow-growing non-Hodgkin lymphomas (NHLs). The study found that the best radiotherapy dose for slow-growing NHLs is 24 Gy in 12 parts after a 5-year follow-up. Some background The current standard of care for...

Read More

Is omarigliptin safe and effective in insulin-treated patients with uncontrolled type 2 diabetes?

Is omarigliptin safe and effective in insulin-treated patients with uncontrolled type 2 diabetes?

Posted by on Feb 28, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the use of omarigliptin (Marizev) in insulin-treated patients with uncontrolled type 2 diabetes (T2D). It found that omarigliptin was well-tolerated and improved blood glucose control.  Some background Type 2 diabetes (T2D) is usually treated initially with diet, exercise, and...

Read More

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...

Read More

Reduced risk of heart failure hospitalizations in patients with type 2 diabetes using SGLT-2 inhibitors

Reduced risk of heart failure hospitalizations in patients with type 2 diabetes using SGLT-2 inhibitors

Posted by on Feb 28, 2021 in Diabetes mellitus | 0 comments

In a nutshell This review focused on the effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on heart failure hospitalization in patients with type 2 diabetes (T2D). This analysis showed that SGLT-2is may reduce the risk of heart failure hospitalizations in these patients. Some background Patients with T2D have a higher risk of developing...

Read More

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Posted by on Feb 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study compared a combination therapy of carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone (Decadron), and cyclophosphamide (Cytoxan) to control combination therapies as an alternative treatment regimen in newly diagnosed patients with multiple myeloma (MM).   The authors concluded that this regimen provided very good...

Read More

Evaluating the long-term outcomes of regional (hockey-stick) prostate cryoablation in men with low- or intermediate-risk prostate cancer

Evaluating the long-term outcomes of regional (hockey-stick) prostate cryoablation in men with low- or intermediate-risk prostate cancer

Posted by on Feb 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and quality of life outcomes after prostate cryoablation (a process that uses extreme cold to destroy prostate tumor) treatment for patients with low and intermediate-risk prostate cancer (PCa). The data showed that the treatment had good outcomes with minimal impact on urinary and sexual...

Read More

Long-term outcomes for sacral neuromodulation for lower urinary tract dysfunction.

Long-term outcomes for sacral neuromodulation for lower urinary tract dysfunction.

Posted by on Feb 27, 2021 in Overactive bladder | 0 comments

In a nutshell This trial looked at the long-term outcomes of sacral neuromodulation (SNM) for patients with overactive bladder (OAB). The authors found that SNM was a minimally invasive procedure with good long-term success rates.  Some background SNM one of several treatment options for the symptoms of OAB, retention and voiding issues...

Read More

Comparing thulium laser enucleation to bipolar resection to treat benign prostatic hyperplasia

Comparing thulium laser enucleation to bipolar resection to treat benign prostatic hyperplasia

Posted by on Feb 27, 2021 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study looked at functional outcomes of transurethral thulium laser enucleation (THU) versus bipolar transurethral resection of the prostate (TURP) for benign prostate hyperplasia (BPH) over 12-months. The authors found that THU may have better effects than TURP. Some background BPH is the non-cancerous increase in the size...

Read More